Trikafta Dosing

昂拓生物完成超5000万美元a轮融资：加速核酸药物管线深度布局新冠肺炎新浪新闻

昂拓生物（arnatar）完成近亿元种子轮融资创投之家

常染色体显性多囊肾病 Adpkd 试验参与者中托伐普坦相关肝损伤的临床模式：关键临床试验分析american Journal Of

Magstone Law Magstone Law

Arnatar Debuts With 52m To Advance Rna Therapies That Go Beyond

昂拓生物完成a轮超5000万美元融资，加速核酸药物管线深度布局新冠肺炎新浪新闻

Stopping Adpkd Progression What We Know And What We Can Do Now

Arnatar Debuts With 52m To Advance Rna Therapies That Go Beyond

Arnatar Unveils With 52m Dual Modality Rna Platform And Rare Disease

Arnatar Debuts With 52m To Advance Rna Therapies That Go Beyond

Arnatar Debuts With 52m To Advance Rna Therapies That Go Beyond

Arnatar Debuts With 52m To Advance Rna Therapies That Go Beyond